| answer text |
<p>In 2021, we announced an additional £5.9 billion to support elective recovery,
diagnostics and technology in the next three years. This includes £2.3 billion to
increase the volume of diagnostic activity and launch community diagnostic centres
to increase capacity for clinical tests, such as phlebotomy for the diagnosis of suspected
blood cancers.</p><p>We have also committed an additional £15.7 billion from April
2022 to March 2025 for managing the ongoing impact of COVID-19, while reducing waiting
times for elective care, including cancer treatments.</p>
|
 |
